12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exjade deferasirox regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Nov. 8 to discuss an sNDA from Novartis for Exjade deferasirox to expand the label...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >